Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Woodville South, Australia Clinical Trials

A listing of Woodville South, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (27) clinical trials

A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver

This is a single center, open-label study to evaluate the safety, tolerability, and effect on tumor growth and symptomology (clinical and biomarkers) following a single intralesional injection of PV-10 in subjects with neuroendocrine tumors metastatic to the liver. Subjects will be divided into two cohorts (up to 6 subjects in …

Phase

0.0 miles

Learn More »

AMG 404 in Patients With Advanced Solid Tumors.

To evaluate the safety and tolerability of AMG 404, a monoclonal antibody that binds to PD-1 and inhibits its engagement with ligands, in patients with advanced solid tumors.

Phase

0.0 miles

Learn More »

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal Gastroesophageal and Renal Cancers

This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose and preliminary efficacy of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma.

Phase

0.0 miles

Learn More »

A Biomarker-directed Study of XPro1595 in Patients With Mild to Moderate Alzheimer's

The study is designed as a multicentre, phase 1b open-label study. The objectives of this study are to determine the safety, tolerability, and efficacy of XPro1595 in patients with mild to moderate Alzheimer's disease and elevated blood levels of the inflammatory biomarker high sensitivity c-reactive protein (hs-CRP). XPro1595 is a …

Phase

0.0 miles

Learn More »

A Study of Itolizumab (EQ001) to Evaluate the Safety Tolerability PK PD and Clinical Activity in Uncontrolled Asthma

The study will enroll up to 40 subjects, with up to 5 dose escalating cohorts of 8 patients enrolled in a 3:1 ratio. Subjects will receive either itolizumab or placebo administered subcutaneously every two weeks (over 8 weeks) for a total of 5 doses with 4 weeks of follow-up.

Phase

0.0 miles

Learn More »

Study of AMG 650 in Adult Participants With Advanced Solid Tumors

To evaluate the safety and tolerability of AMG 650 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

Phase

0.0 miles

Learn More »

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of venetoclax in pediatric and young adult participants with relapsed or refractory malignancies.

Phase

3.98 miles

Learn More »

Study of TG-1701 an Irreversible Bruton's Tyrosine Kinase Inhibitor in Patients With B-Cell Malignancies

This Phase I clinical trial aims to evaluate the safety of the investigational drug TG-1701 both as a single-agent and in combination with other investigational drugs, specifically ublituximab and umbralisib.

Phase

4.96 miles

Learn More »

A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies

There are two stages in this study: a dose-escalation stage (stage 1) and a dose-expansion stage (stage 2). Dose-escalation stage (stage 1). The conventional 3+3 design (3 patients per dose cohort, with the potential to add additional 3 patients to the same cohort to further evaluate toxicity) will be applied …

Phase

4.96 miles

Learn More »

Safety Tolerability and Pharmacokinetics of HSK21542 in Healthy Volunteers

This is a A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of a kappa receptor agonist HSK21542 in Healthy Volunteers. The study will enroll approximately 50 adults. The anticipated study duration will be up to 6 months.

Phase

4.96 miles

Learn More »